NCT06774326 Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines
| NCT ID | NCT06774326 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Cardiac Imaging |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-02-14 |
| Primary Completion | 2029-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2024-02-14 with a primary completion date of 2029-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the diagnostic capability of Spectral CT (performed with contrast agent as part of routine oncological follow-up) in detecting signs of acute and chronic early-onset cardiac toxicity from anthracyclines in patients with Hodgkin's lymphoma and diffuse large B-cell lymphoma undergoing treatment regimens that include a drug from this family.
Eligibility Criteria
Inclusion Criteria: * Patients with Hodgkin's lymphoma or diffuse large B-cell lymphoma (DLBCL) undergoing treatment regimens including anthracyclines * Age ≥18 years * Informed consent obtained Exclusion Criteria: * Absolute or relative contraindications to CT examination and/or administration of iodinated contrast agents (e.g., pregnancy, severe renal insufficiency in non-dialysis patients with GFR \<15-30 ml/min/1.73m²). * Patients with a concomitant positive history of cardiovascular disease (e.g., myocardial infarction, known coronary artery disease, heart failure, arrhythmias, prior myocarditis, cardiomyopathies). * History of mediastinal radiotherapy.
Contact & Investigator
Vincenzo Russo, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06774326 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Imaging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06774326 currently recruiting?
Yes, NCT06774326 is actively recruiting participants. Contact the research team at vincenzo.russo@aosp.bo.it for enrollment information.
Where is the NCT06774326 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06774326 clinical trial?
NCT06774326 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Vincenzo Russo, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 160 participants.